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Children with Down syndrome (DS), adolescents/young
adults (AYA), and infants with high-risk and relapsed
leukemia face distinct challenges during and after hemato-
poietic stem cell transplantation (HSCT). In this review, we
examine the unique aspects of HSCT for these patients,
including the risk of transplantation-related toxicity,
psychosocial concerns, and the potential for late effects.
HSCT IN CHILDREN WITH DOWN SYNDROME
Children with DS are at 10%-30% greater risk for devel-
oping acute leukemia [1,2]. A recent study found similar
relapse and survival rates for acute lymphoblastic leukemia
(ALL) in children with DS and those without DS [3]. In acute
myelogenous leukemia (AML), children with DS typically
have better outcomes than children without DS [4]. Despite
the generally favorable disease control in children with
DS and acute leukemia, HSCT may be offered to children
with relapsed and high-risk disease. Childrenwith DS require
special consideration during HSCT because of possible pre-
existing comorbidities and the potential for increased
transplantation toxicity. The optimal transplantation strategy
for a child with DS balances disease control with acceptable
toxicity. Safe and effective HSCT in children with DS is
a uniquely pediatric issue, given that we are not aware of any
reports of adults with DS undergoing HSCT.
Toxicity
It is well documented that children with DS experience
greater chemotherapy-associated toxicity and excess
treatment-related mortality during leukemia therapy
compared with children without DS [5]. It is not clear from
the published literature that this is true during HSCT or
that increased toxicity is associated with an increased risk
for transplantation-related mortality (TRM). Early studies
of children with DS undergoing HSCT reported TRM rates
between 39% and 75% [6-8]. In these reports, TRM excee-
ded leukemia relapse as the cause of death. Respiratory
and airway toxicities, including pulmonary hemorrhage,
pneumonitis, and upper airway obstruction due to severe
mucositis, were common in early reports, and fatal
pulmonary toxicity has been reported in as many as 26% of
patients [6-8]. Causes of the high rate of pulmonary
toxicity are unclear in these reports; however, respiratoryFinancial disclosure: See Acknowledgment on page S56.
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abnormalities, and cystic lung disease, are well described in
children with DS. The literature suggests that respiratory
illnesses are the most common reason for hospitalization
for children with DS [9]. Pulmonary vascular abnormalities
predispose some children with DS to pulmonary hemor-
rhage, pulmonary edema, and pulmonary hypertension.
Sleep-disordered breathing commonlyaffects childrenwith
DS and can result inpulmonary hypertension. It is likely that
underlying pulmonary disease contributes to the incidence
of respiratory complications of HSCT in children with DS.
Published guidelines and recommendations for anticipa-
tory guidance in children with DS stress screening for
obstructive sleep apnea and vigilance for the presence of
asymptomatic pulmonary hypertension [10]. There are no
guidelines for pretransplantation screening for children
with DS. Providers should familiarize themselves with both
the common and less common respiratory complications
associated with DS and tailor pre-HSCT screening to indi-
vidual patients based on the child’s clinical history.
A more recent retrospective study of 11 children with DS
who underwent HSCT showed improvement in TRM, with
a day 100mortality of 18% [11]. In that report, relapsewas the
most frequent cause of posttransplantation mortality, with
a 45% incidence of death due to recurrent disease [11]. The
authors suggested that the decrease in TRM may be related
improved supportive care and advances in HLA typing.
Another potential contributing factor may be increased
experience with HSCT in children with DS. In early reports,
fewer children with DS underwent HSCT than predicted. In
1988, Arenson and Forde [6] reported that only approxi-
mately 25% of children with DS who qualiﬁed for HSCT as
predicted by disease occurrence and expected treatment
response actually underwent HSCT in the United States [6].
The authors suggested multiple reasons for the lower than
predicted rate of HSCT in this population, including the
possibility of smaller families in children with DS, making it
more challenging to ﬁnd matched related donors; the pres-
ence of coexisting medical conditions that could be prohib-
itive to transplantation, intolerance of pretransplantation
therapy; parental refusal; and physician bias. They could not
ﬁnd sufﬁcient evidence supporting any of these factors,
however, and the reasons for the low rate of HSCT in children
with DS remain unclear.
Conditioning
The increased risk of chemotherapy-associated toxicity
has raised concerns about the ability of children with DS toTransplantation.
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large prospective published series of HSCT in patients with
DS. In the 2 largest published series to date, conditioning
regimens included myeloablative doses of at least one of the
following: total body irradiation (TBI), cyclophosphamide,
and busulfan. In a review of 27 patients, Rubin et al. [8] re-
ported no signiﬁcant association between the use of any of
these agents and day 100 mortality. The combination of
cyclophosphamide and TBI appeared to be associated with
greater toxicity, although this could not demonstrated
deﬁnitively owing to the relatively small number of patients.
Meissner et al. [11] did not report early mortality associated
with any particular conditioning regimen, though that study
was also limited by a small number of patients. The results of
these and smaller studies strongly suggest that children
with DS can tolerate myeloablative conditioning regimens
without excess mortality.
Graft-versus-Host Disease
Rates of acute graft-versus-host disease (aGVHD) in
children with DS are inconsistent across studies and range
between 25% and 100%, with the skin the most commonly
affected organ [7,11]. Rates of chronic graft-versus-host
disease (cGVHD) are not signiﬁcantly different in children
with DS and those without DS [11]. Multiple GVHD prophy-
laxis regimens have been used, including T cell depletion,
methotrexate (MTX), corticosteroids, cyclosporine, azathio-
prine, antithymocyte globulin, and mycophenolate mofetil.
The use of MTX as part of GVHD prevention strategies is
controversial, given reports of poorer drug tolerance in
children with DS when included in therapy for ALL [12].
Buitenkamp et al. [ ] reported a more than 6-fold increased
incidence of grade III-IV gastrointestinal toxicity, including
mucositis, compared with non-DS children receiving
MTX for leukemia therapy. MTX clearance measured in
pharmacokinetic assays was lower in children with DS, but
there was no difference in 24- or 48-hour levels. The authors
concluded that the increased toxicity seen in DS patients is
related to differences in tissue response and not to plasma
drug levels.
It should be noted that the doses of MTX used in GVHD
prophylaxis regimens are lower than those in leukemia
protocols, and that approximately 50% of the GVHD regimens
used in the largest published transplant series of children
with DS have includedMTX. In 1996, Rubin et al. [8] reported
an association between the use of MTX and early death
compared the use of cyclosporine A. This association has
not been shown in other studies, however. All of the
published reports are retrospective in nature and have
limited patient numbers, hindering assessment of whether
MTX causes excess toxicity in childrenwith DS when used as
part of a GVHD prevention strategy. The existing evidence
does not clearly support an assertion that children with DS
cannot safely receive MTX as GVHD prophylaxis; nonethe-
less, providers may consider the use of MTX-sparing
regimens for children with DS. This may be advised for
patients with increased potential for airway compromise
with MTX.
Conclusion
Acute leukemia is more common in childrenwith DS than
in those without DS. The available literature indicates that
children with DS can tolerate myeloablative conditioning
regimens and MTX-containing GVHD prophylaxis strategies.
However, providers need to be mindful of preexistingcomorbidities, such as obstructive sleep apena and upper
airway abnormalities, when devising treatment plans for
these children.
CHALLENGES FACING THE AYA ONCOLOGY AND HSCT
POPULATION
Introduction
Although cancer in the AYA population has received
increasing attention in recent years, HSCT in this population
has not been well studied. In 2005, the National Cancer
Institute (NCI) and the Lance Armstrong Foundation (LAF)
sponsored the Adolescent and Young Adult Oncology Prog-
ress Review Group (AYAO PRG), which was charged with
evaluating the biological, biomedical, and psychological
challenges particular to the AYA oncology population [13].
Based on the work of the AYAO PRG, the LiveStrong Young
Adult Alliance was formed, which published recommenda-
tions to improve care for the AYA population, including
timely detection; efﬁcient processes for diagnosis, initiation
of treatment, and promotion of adherence; access to health
care professionals with knowledge speciﬁc to the biomedical
and psychosocial needs of this population; and research that
will ultimately develop objective criteria for the develop-
ment of AYA oncology care guidelines [13,14]. This pop-
ulation is of particular interest for improvement in care,
given the signiﬁcant economic and psychosocial impact of
loss of life in this age group.
The AYAO PRG designated AYA as encompassing age
15-39 years. The incidence of cancer in persons aged 15-29
years has increased over the past 25 years, and cancer is now
the second-leading cause of nonaccidental death in persons
aged 15-24 years [13,14]. Over the past 30 years, the AYA
population has not beneﬁted from the same dramatic
improvement in outcomes seen in both children and older
adults with cancer [15]. Outcomes in the AYA population
remain stubbornly stable, owing to a complicated set of
medical and psychosocial challenges.
Medical Issues
From a medical standpoint, there are several concerns
unique to the AYA population. This population is subject to
delays in diagnosis, resulting in worse prognosis, because
patients are sicker and have more advanced disease at the
eventual initiation of therapy [16]. In addition, the diseases
in this age group often have distinct biological characteris-
tics that confer a worse prognosis compared with other age
groups; for example, breast cancer and colon cancer are
more aggressive and have distinct biological characteristics
in this age group compared with older adults [17].
Compared with younger children with ALL, AYA patients
with ALL have a lower rate of cytogenetic changes heralding
good prognosis, such as triple trisomies of 4, 10, and 17 and
t(12;21), and a higher rate of cytogenetics associated with
poor prognosis, including t(9;22) [18]. Furthermore, AYA
patients with ALL have a worse prognosis even without
high-risk cytogenetic changes. One study found a higher
incidence of JAK mutations and IKZF1 deletions in the AYA
population, raising the possibility of targeted therapy [19].
With regard to HSCT, children and adolescents have lower
rates of GVHD and TRM than adult patients, but adolescents
have higher rates than younger children [20]. Older adults
have higher rates of TRM compared with younger adults,
necessitating reduced-intensity conditioning regimens in
many cases [21]. Rates of transplantation-related compli-
cations in the AYA population have not been well
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rate of second primary malignancies in the AYA population,
some therapy-related and some from known genetic
predisposition [22].
Data show that adolescents with more traditionally
pediatric diseases, including ALL and Ewing sarcoma, have
better outcomes when treated at pediatric centers, whereas
those with more traditionally adult cancers, such as breast or
colorectal cancer, fare better at adult centers [23,24]. The lack
of improvement in outcomes for the AYA group may be
related to decreased enrollment in clinical trials. Whereas up
to 45.4% of 5- to 9-year-old patients are enrolled in clinical
trials, only 13.8% of patients in the 15- to 19-year-old age
range and a dismal 2.2% of those in the 25- to 29-year group
participate in trials [25]. This is due in part to a relative lack of
available trials for this group, including registry and banking
studies. AYA patients treated at adult centers have lower
enrollment in clinical trials than those treated at pediatric
centers, often because trials that are available through the
Children’s Oncology Group might not be available at adult
centers [23,26]. The development of an AYA program that
improves communication between pediatric and adult
centers has been shown to reverse this trend and increase
clinical trial enrollment [27].
The different clinical pharmacology in the AYA age group
compared with older and younger groups could affect
outcomes related to either underdelivery or overdelivery of
drug therapy. The hormonal changes associated with growth
and puberty; obesity affecting the volume of drug distribu-
tion; size and maturity of the liver and kidneys; use of
tobacco, alcohol, and illicit drugs; and absorption due to low
gastric pH have all been implicated as factors in clinical
pharmacology in the AYA population [28]. There is a paucity
of data regarding the pharmacokinetics of most of the
commonly used SCT medications in this population.
Fertility issues are of particular concern for the AYA
population, with 73% of young cancer survivors expressing
a desire for future children [29,30]. However, 30%-60% of
survivors do not recall receiving information about risks to
fertility at the time of their cancer diagnosis [29,31]. In some
of these cases, information might have been given to the
parents instead of to the adolescents, or might not be
recalled owing to the shock of the diagnosis [30]. For male
patients, sperm banking should be discussed and literature
offered in language appropriate to the patient’s age and
maturity level and should be scheduled before the initiation
of therapy whenever feasible. Successful pregnancies have
been reported from sperm stored for as long as 28 years [32].
Young adolescents and patients with Hodgkin lymphoma are
less likely to have adequate viable sperm counts [33].
Fertility preservation is much more complicated in the
female AYA population. A randomized controlled study in
patients with breast cancer showed signiﬁcantly less ovarian
failure at 8 months posttherapy in patients treated with
gonadotropin-releasing hormone analogs [34]. Embryo
cryopreservation, in patients in whom therapy can be safely
delayed for 10-14 days, can be a good option for AYA patients
with a dedicated male partner [30]. Oocyte cryopreservation
has become more successful, with more than 900 live births
reported, but again requires a delay in therapy for hormonal
stimulation [35]. Ovarian tissue freezing does not require
a delay, but carries the risk of a laparoscopic procedure and
the theoretical risk of preserving then reimplanting malig-
nant cells harbored in the ovary, and to date there have been
only a handful of reported successful pregnancies with thisapproach. Barriers to effective fertility preservation include
inability to delay therapy, ﬁnancial concerns, lack of time or
knowledge of the treating oncologist, and lack of awareness
of appropriate referral sites [30,36].
Psychosocial Issues
One issue facing the AYA population is decreased
healthcare utilization. In some countries, this may be related
to low rates of health insurance coverage [25]. It also may be
attributed to the unique set of demands on this group,
including ﬁnishing school, starting a career, raising a family,
and caring for aging relatives. Psychosocially, this age group
has a sense of invincibility and a blossoming desire for
autonomy that might keep them from seeking medical
advice [23].
Although objective data are scarce, rates of noncompli-
ance with treatment regimens in the AYA oncology pop-
ulation appear to range from 27%-60% [37]. Adherence is
particularly poor in adolescent oncology patients, and poor
compliance has been documented in adolescents with other
chronic illnesses as well [37]. Interestingly, one study in the
AYA SCT population has shown better adherence in adoles-
cents than in younger patients [26]. Adherence may be
difﬁcult for the AYA population, who may be more keenly
affected by therapy-induced body image changes and
disruption of social and work schedules [23,38]. Full
involvement of the AYA patient in treatment planning, ﬂex-
ibility of scheduling to allow for important life events when
possible, use of reminders via technology such as text or
e-mail, and nonjudgmental monitoring and review can
improve adherence rates [37]. Such ﬂexibility can be partic-
ularly difﬁcult to reconcile with post-HSCT restrictions.
Regarding psychosocial support, in one study, health
care providers ranked the importance of support from
family and friends as of utmost importance for the AYA
group, whereas the patients ranked contact with other AYA
survivors of greater importance, again emphasizing the
importance of peer contact in this age group [38]. In
psychological follow-up testing, survivors of AYA cancer
demonstrated similar overall measures of psychological
distress and health-related quality of life as controls [39].
However, they have fewer positive health beliefs and
greater psychological distress, including posttraumatic
stress symptoms, compared with cancer survivors who
were diagnosed earlier in childhood [39].
AYA Programs
There is interest in establishing dedicated AYA oncology
programs to provide superlative care to this population. The
United Kingdom has forged ahead with stand-alone Teenage
Cancer Trust facilities specially designed for the AYA pop-
ulationwith designated spaces and a team of specialists [40].
Where this is not feasible, other centers have established
“virtual centers” within existing programs [40]. In some
centers, rather than tackle the entire AYA issue, disease-
speciﬁc AYA programs, such as those for breast cancer,
have been established [40].
Establishing an AYA program requires a new paradigm
that differs from the established pediatric and adult para-
digms. The predominantly family-focused model of care in
pediatrics and the predominantly disease-focused model of
care in adult internal medicine should bemerged into a more
multidisciplinary patient-focused model appropriate for the
AYA group. In 2011, Ramphal et al. [23] laid out a series of
recommendations for improving care in the AYA population,
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collaboration between adult and pediatric centers, educating
primary care providers about AYA oncology diagnoses,
enhancing supportive care resources, and optimizing the
clinical environment for the AYA population. The authors
stressed that ideal models of care for this group need to
encompass medical care, psychosocial support, and an age-
appropriate physical environment. It is important to iden-
tify a dedicated multidisciplinary group of providers
including those with disease expertise and a full range of
subspecialists including fertility experts, a palliative care
team, and strong psychosocial support. Psychosocial support
should encompass ﬁnancial, school, parenting, and career
concerns. Barriers to implementing this ideal model include
lack of awareness of AYA issues among providers, the public,
and health organizations; poor communication between
adult and pediatric oncology providers; lack of funding; and
geographical challenges.
Conclusion
This is an exciting time in the AYA ﬁeld as work prog-
resses on better understanding and addressing the unique
challenges that have stagnated progress in outcomes for this
group. Many of the medical and psychosocial issues are the
same for the AYA oncology and HSCT populations; however,
further research into the biological characteristics of the AYA
HSCT population is needed to optimize therapy and decrease
toxicity.
HSCT IN INFANT ALL
Improvements in survival for infants with ALL have not
matched the progress seen in older children with leukemia,
in whom survival rates have improved steadily over time
[41,42]. This is especially true when the leukemia is charac-
terized by MLL gene rearrangements. MLL-rearranged
leukemia in infants has a unique gene expression proﬁle and
is associated with an increased risk of relapsed and poor
prognosis [43,44]. Because of the poor prognosis, infants
with this disease are typically treated with intensiﬁed
chemotherapy regimens. Unfortunately, this strategy has not
resulted in acceptable event-free survival (EFS) rates in
consortia studies. Using a cytarabine-intensive treatment
regimen, the international Interfant clinical trials group re-
ported a 5-year EFS of 37% for infants with MLL-translocated
leukemia [45]. The Children’s Oncology Group (COG) re-
ported a 5-year EFS of 34% using a chemotherapy regimen
that included high-dose MTX, cyclophosphamide, and eto-
poside [46]. The Dana-Farber Consortium achieved 43% long-
term survival in infants with MLL gene rearrangements
treated with an intensiﬁed regimen, although the number of
patients in this study was limited [47].
The role of allogeneic HSCT during ﬁrst clinical remission
(CR1) in infants with ALL is unclear. A group from the Fred
Hutchinson Cancer Research Center reported outcomes of 40
patients diagnosed with ALL at age <12 months who
underwent allogeneic HSCT with myeloablative conditioning
[48]. The estimated probability of survival at 3 years was 50%
(95% conﬁdence interval, 34.3%-65.4%), with the probability
of relapse dependent on remission status at the time of
transplantation. The estimated probability of relapse at
1 year post-HSCT was 12% for patients undergoing trans-
plantation in CR1 and 43% for those in second or third clinical
remission. In this series, 76% of patients with evaluable
cytogenetics had anMLL rearrangement, and the presence of
theMLL gene rearrangement was not associatedwith inferioroutcome. Other groups have have reported similarly
encouraging results [49,50].
These results contrast with those of other investigators
showing disappointing survival rates [51]. A analysis of
consortia and single-center HSCT outcomes in 28 infants
with ALL characterized by 11q23 abnormalities who under-
went myeloablative HSCT reported no improvement in
disease-free survival compared with children who received
chemotherapy alone, regardless of donor source [52]. In
a Japanese trial, all infants with MLL rearrangement were
scheduled to proceed to allogeneic HSCT from the best
available donor by 3-5 months after diagnosis [53]. The
3-year EFS was 44% for all enrolled infants, 54.4% for infants
who survived to HSCT, and 64.4% for those who underwent
HSCT in CR1. Evenwith intensive upfront chemotherapy, 27%
of infants with MLL rearrangement who achieved initial CR1
relapsed before HSCT. A COG study that included 189 infants
treated on infant ALL protocols between 1996 and 2000 re-
ported no difference in EFS between infants who underwent
HSCT in CR1 and those who received chemotherapy alone
[54]. The Interfant-99 trial found no difference in disease-
free survival in high-risk infants and those with MLL trans-
locations treated with either allogeneic HSCT in CR1 or
chemotherapy alone [45]. However, in a subset analysis,
HSCT in CR1 was associated with a signiﬁcantly better
disease-free survival in infants withMLL translocations aged
<6 months at diagnosis and either a poor response to
steroids at day 8 or a leukocyte count300 g/L. In this subset
of infants, HSCT in CR1 was associated with a 64% reduction
in the risk of failure resulting from relapse or death
compared with chemotherapy alone.
The lack of clarity in the data and relatively small number
of patients in each series makes it difﬁcult to recommend
upfront allogeneic HSCT to all infants will ALL. However, the
cure rate for infants undergoing HSCT in second clinical
remission or greater is dismal, and the literature suggests
that certain infants with high-risk features, including MLL
translocations, age <6 months, and poor response to initial
therapy, may beneﬁt from HSCT [48,55].
Late Effects
All leukemia-directed therapeutic strategies for infants
must balance the probability of cure with the risk of late
effects. This is especially true for HSCT, given that the indi-
cation for transplantation is controversial and the potential
for late effects is great. There are few reports of the long-term
side effects of HSCT in children undergoing transplantation
for hematologic malignancy at age<12 months, likely due to
the small numbers of patients who undergo transplantation
for infantile leukemia and the high risk of post-
transplantation relapse. A study of 17 children undergoing
HSCT for infant ALL conditioned with a TBI-containing
regimen (13.2-15.75 Gy) and surviving for more than 1
year posttransplantation reported no devastating late effects
[48]. In this series, osteopenia were commonly reported late
toxicities included short stature, dental abnormalities, and
cataracts. Neuropsychiatric functioning was assessed in 15
patients; 3 had normal development, 4 had average to
slightly delayed motor function, 1 had motor delay, 6 had
speech delay, and 1 had delayed speech and motor function.
The authors concluded that severe devastating late effects
did not occur when the only cranial irradiation was 13.20-
15.75 Gy administered as fractionated TBI. Those ﬁndings
differ from those of Leung et al. [56], who reported late
effects of survivors of infants with leukemia treated with
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those who received chemotherapy alone or chemotherapy
with cranial radiation without HSCT. Data showed greater
loss of height, incidence of cataracts, and neurocognitive
challenges in the HSCT recipients. Severe neurocognitive
disturbances were diagnosed in 2 of 7 evaluable patients.
Younger age at transplantation was associated with greater
risk of learning difﬁculties. Both of the foregoing studies are
limited by small patient numbers, however, and larger case
series are needed to better understand the risk of late effects
in this population.
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